drugset / Trial / NCT06151197

Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)

NCT06151197

Phase 3 Completed 436 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).

Timeline

Start
2023-11-28
Primary completion
2026-06-09
Completion
2026-06-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic Other

Indications